Monopar Therapeutics Inc.
Price Action
Technical Summary
CONSOLIDATINGMonopar Therapeutics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 93), indicating clear outperformance against the broad market. Earnings contraction of 21% provides fundamental context to the price action. However, with RSI at 82, the stock is extended and may be prone to a short-term pullback.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $77.11 | +23.48% | ABOVE |
| 50 SMA | $66.67 | +42.82% | ABOVE |
| 100 SMA | $61.41 | +55.07% | ABOVE |
| 150 SMA | $63.98 | +48.82% | ABOVE |
| 200 SMA | $68.91 | +38.17% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MNPR in an uptrend right now?
MNPR has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is MNPR overbought or oversold?
MNPR's RSI (14) is 82. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is MNPR outperforming the market?
MNPR has a Relative Strength (RS) Rating of 93 out of 99. Yes, MNPR is a market leader, outperforming 93% of all stocks over the past 12 months.
Where is MNPR in its 52-week range?
MNPR is trading at $95.22, which is 91% of its 52-week high ($105.00) and 87% above its 52-week low ($29.18).
How volatile is MNPR?
MNPR has a Beta of 1.60 and 52-week volatility of 81%. It's more volatile than the S&P 500 - expect bigger swings.